posted on 2017-03-31, 15:01authored byBenjamin M. Kelly, Soteris Xenophontos, James KingJames King, Myra A. Nimmo
Both sprint interval training (SIT) and high-intensity intermittent training (HIIT) have been described as time-efficient strategies for inducing favourable metabolic and cardiorespiratory adaptations in healthy and diseased participants. BACKGROUND: To date, little attention has been given to profiling the potential health benefits of HIIT or modified HIIT training within overweight and obese cohorts with particular focus on inflammation. Within this pilot trial, we tested the hypothesis that 6 sessions of HIIT performed over 2 weeks with 1-2 days’rest would improve aerobic capacity, glucose metabolism and inflammatory profile in an overweight and obese male cohort. Additionally, we profiled the potential health benefits of 4
HIIT sessions performed over the same period. METHODS: 18 overweight or obese males (BMI = 31.2 ± 3.6; V̇O2 = 30.3 ± 4.4 ml.kg.min-1) were studied before and 72 h after HIIT.
Training sessions consisted of 10 x 1 min intervals at 90% HRpeak separated by 1 min
recovery periods. Exercise was performed either 6 (group 1, n = 8) or 4 (group 2, n = 10)times over a 2 week period. RESULTS: After training no changes were detected from
baseline for body composition, aerobic capacity, glucose metabolism or inflammatory profile(p > 0.05) in either group. CONCLUSION: Both 6 and 4 sessions of HIIT performed over a 2-week period are ineffective in improving selected health markers within an overweight and obese cohort.
Funding
This research was supported by the National Institute for Health Research (NIHR) Diet,
Lifestyle & Physical Activity Biomedical Research Unit based at University Hospitals Leicester and Loughborough University.
History
School
Sport, Exercise and Health Sciences
Published in
BMC Obesity
Citation
KELLY, B.M. ... et al, 2017. An evaluation of low volume high-intensity intermittent training (HIIT) for health risk reduction in overweight and obese men. BMC Obesity, 4 (17).
This work is made available according to the conditions of the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Full details of this licence are available at: http://creativecommons.org/licenses/ by/4.0/
Acceptance date
2017-03-14
Publication date
2017-04-19
Notes
This is an Open Access Article. It is published by BioMed Central under the Creative Commons Attribution 4.0 International Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/.